-
Acta Neuropathologica: SFPQ and Tau: Key factors leading to the rapid development of Alzheimer's disease.
Time of Update: 2020-09-25
Is consistent with the results from the human brain, in-body studies in this paper show that SFPQ is recruited into TIA-1 positive stress particles (SGs) after oxidative stress induction, and co-located with tau/p-tau in these particles, providing a possible mechanism for causing SFPQ misalposition through pathological SGs.
-
JNNP: The frequency of diabetes and other complications in chronic inflammatory demyelinative multiple neurogen disease and its effect on clinical manifestations and treatment responses.
Time of Update: 2020-09-25
Objective: To determine the prevalence of different cogens in chronic inflammatory demyelinative multiple neuropathy (CIDP) and its effect on outcome, treatment choice and response.
incidence of diabetes (14%), MGUS (12%) and other immunologic diseases (16%) among CIDP patients was significantly higher than in the European general population.
-
Alzheimer's and Dementia: Drugs to correct micro-tube defects promise to treat Alzheimer's disease.
Time of Update: 2020-09-25
The brain of Alzheimer's disease (AD) patients is characterized by extracellular aging plaques consisting of amyloid beta (A beta) peptides, as well as intracellular enveraged bodies formed by tau proteins, commonly known as nerve fiber tangles.
-
JNNP: Radiological diagnosis of spinal nod disease.
Time of Update: 2020-09-25
spinal nod disease is rare (5 per cent of patients with nodding), and diagnosis is often challenging given its different clinical manifestations and nonse specific abnormalities that occur after radiology, laboratory and electrophysiological examinations.
-
Ann Neurol: The association between plasma nerve wire light chain protein and postoperative delirium.
Time of Update: 2020-09-25
increased risk of delirium in patients with PREOP and POD2 NfL in the highest quarterile (Q4) range (adjusted OR=3.7 (95% CI 1.1-12.6) and 4.6 (1.2-18.2) respectively) and experienced more severe delirium, Cam-S scores 7.8 (95% CI 1.6-14.0) and 9.3 (95% CI 3.2-15.5).
-
JNNP: Mild cognitive impairment and neurological inflammation and cerebrovascular disease in patients with Alzheimer's disease.
Time of Update: 2020-09-25
the overall SVD level, the combined score of SVD subsypes of hypertension artery disease and cerebral amyloid vascular disease (CAA).
. glial cell activation is associated with SVD, especially with the subtype of hypertensive artery disease in SVD.
-
Nat Commun: Don't you consider a lunch break? Brain ridge fluid pours into brain at noon to 'clean up', study says
Time of Update: 2020-09-25
these results showed that the cerebrospinal fluid tracer's lymphatic inflow to the brain showed day-night changes regardless of the state of the anaesthetic, and peaked around noon, when the mice were most likely to fall asleep.
-
CELL: Neural path paths leading to hedonic overempeding and obesity have been revealed.
Time of Update: 2020-09-25
this stage is followed by the consumption phase, including the feeling, exercise, and reward processes associated with achieving behavioral goals (e.g., eating food or drinking water).
periLCVGLUT2 neurons are moderately and steady-state in the consumption process and need to be inhibited scalablely.
-
Science: Do women get up early and men like to stay up late? Reveal the gender differences of the biological clock.
Time of Update: 2020-09-25
in a review published in Science on September 5, Beijing time, two researchers from the University of Pennsylvania in the United States analyzed a large number of studies of circadian rhythms and found a pattern: gender differences in circadian rhythms.
-
JNNP: The role of cerebrospinal fluid phosphate nerve wire heavy chains and shell triglycoside enzymes in primary lateral sclerosis.
Time of Update: 2020-09-25
Although the level of cerebrospinal fluid (CSF) nerve wire in ALS increased significantly, making it a recognized ALS biomarker that reflects axis mutations, the authors measured phosphatized neural strands (pNFH) and Chit1 in cerebrospinal fluid in patients with PLS, ALS and non-neurodegenerative neurological disorders.
-
Challenge 25 years of consensus! The Alzheimer's vaccine is about to begin Phase III clinical trials, and the company's sword refers to the tau protein Achilles.
Time of Update: 2020-09-25
study found that the pathological form of tau protein, rather than beta amyloid protein, was a key driver of AD.
the past six years or so, many large pharmaceutical companies have started to study tau proteins," said Zillka, a pharmaceutical researcher.
-
Parkinson's gene therapy! 3 years after NBIb-1817 one-time drug: Continuously shorten OFF time/extend ON time, improve sports function!
Time of Update: 2020-09-25
September 14, 2020 // -- Neurocrine Biosciences and partner Voyager Therapeutics recently presented data from a three-year open label IB-1101 trial to assess the efficacy and safety of the one-time gene therapy NBIb-1817 (VY-AADC) at the 2020 International Conference on Parkinson's Disease and Movement Disorders (MDS).
-
Neurology: High-resolution MRIs before and during outpost headaches confirm aneurysm wall bleeding.
Time of Update: 2020-09-25
A 1/4 patient before an aneurysm rupture reports an outpostinel headache, which can be interpreted as a warning of oozing from the subcavity cavity of the cobweb or structural wall changes such as stretching or acute wall bleeding.
-
Johnson and Johnson submitted a market application for a new adaptation of Darzalex injections to treat light-chain amyloid degeneration.
Time of Update: 2020-09-25
On September 10, Janssen announced that it had submitted to the FDA an application for a license for a supplemental biologic product for Thedarzalex Faspro (daratumumab/hyaluronoidase-fihj) subsurface injection for the treatment of patients with light-chain amyloid degeneration.
-
Science: There is a problem with the neural circuit, which is repaired by synthesized proteins.
Time of Update: 2020-09-25
CPTX restores PF-PC synapses and motion coordination in mice that the GluD2 gene knocks out, and the researchers synthesized a new synact tissue protein, CPTX, that interacts with pre-synhap neurotoxins and post-synhapamp AMPA ion glutamates and induces the formation of excitable synapses in the body and beyond.
-
Acta Neuropathologica: KBTBD6/7-DRD2 axis regulates the sensitivity of pituitary adenoma to dopamine astration therapy.
Time of Update: 2020-09-25
dopamine astrologists (DAs), such as brominated pavilions (BRC) and carameline (CAB), are a first-line treatment for oxytocinoma because they effectively reduce the secretion of serum oxytocin (PRL) and have been shown to significantly reduce tumor size in about 90% of patients.
DAs mainly activates dopamine type 2 lithums (DRD2) on the surface of pituitary tumor cells.
-
JNNP: Relationship between Smoking and ALS: Mendel Random Causality Survey.
Time of Update: 2020-09-25
used the results of a recently published large genome-wide association study and Mendel randomization method to assess the relationship between smoking and ALS.
genome-wide association study of ALS (20,806 cases; 59,804 controls) was used as a result of deficit-weighted Mendel randomization and four other Mendel randomization methods to test whether smoking was a causal relationship to ALS.
-
Stroke: Reduced systolic blood pressure and acute kidney injury in patients with cerebral hemorrhage.
Time of Update: 2020-09-25
in the multivariate analysis, higher baseline serum creatinine levels (-110μmol/L) were associated with AKI (ratio of 2.4 (95% CI is 1.2-4.5)) and kidney AEs (ratio of 3.1 (95% CI is 1.2-8.1).
-
Vertex "old medicine" to prevent and treat Alzheimer's disease obtains positive animal experiment results
Time of Update: 2020-09-25
recently, a study by a team of professors at McGill University in Canada, Andréa LeBlanc, showed that Vertex' "old drug" delays cognitive impairment in mice before alzheimer's symptoms begin and age.
, the mice the researchers used showed signs of Alzheimer's disease at age 4 months.
-
J INTERN MED: Relationship between calcium channel blockers and survival and ischemic stroke in people with dementia.
Time of Update: 2020-09-25
a recent study published in Journal of Internal Medicine, an authoritative journal in the field of internal medicine, aims to calculate the risk of death and ischemic stroke in people with dementia treated with CCCB and to consider individual drug and dose responses.
